Introduction
The impact of the glycosylation status of immunoglobulins and immunoglobulin (Ig)G-containing immune complexes on disease activity in rheumatoid arthritis (RA) has attracted increased attention in recent years [1] [2] [3] . Immune complex deposition in synovial membranes or blood vessels of skin, kidney and other organs and the accompanying inflammation and tissue damage are associated mechanistically with various autoimmune diseases, such as RA and systemic lupus erythematosus (SLE) [4, 5] . The formation of immune complexes containing autoreactive antibodies is discussed to play a detrimental role in the tissue damaging processes of RA [6] . Deposition of immune complexes in endothelia is thought to foster atherosclerosis and thus offers an explanation for the increased risk of patients with RA to develop cardiovascular pathology [7] . Moreover, there is evidence that IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) are independent risk factors for ischaemic heart disease [6, 8] and increased mortality rates [9] . The presence of autoreactive immunoglobulins such as RF and anti-CCP antibodies is associated with a more severe course of RA [10] [11] [12] [13] [14] . Most circulating immune complexes are captured initially by the complement receptor 1 on the surfaces of erythrocytes. Erythrocytes transport immune complexes to the liver or the spleen, where they are phagocytosed by macrophages and thus cleared from the bloodstream [15] .
The pathogenicity of autoantibodies is essentially influenced by their glycosylation pattern [16] [17] [18] . As depicted in Supporting information, Fig. S1 , several different modifications of the glycan structure are associated with native IgG complexes: (1) the canonical glycans attached to the CH2-domains [14, 19, 20] , (2) the glycans attached to some VH and CH1 domains [21, 22] , (3) putative sites of hyperglycosylation, (4) increased accessibility for lectin binding of the canonical glycans attached to the CH2-domains [23] and (5) glycans attached to non-IgG molecules of the IgG complex [24] [25] [26] .
The aim of this study was to characterize the glycan exposure of IgG-containing immune complexes in patients with recent-onset RA. We observed significant differences in the glycan exposure on immune complexes in patients with RA compared to healthy controls. Several of the lectins displayed an altered, mainly increased, binding to the IgG complexes. Moreover, significant differences of glycan exposure between recent-onset RA and follow-up have been observed.
Material and methods

Patients and control subjects
We studied 30 patients (20 women, 10 men, mean age all 5 57Á4 years, standard deviation (s.d.) all 5 614Á5; mean age women: 54Á7 years, s.d. women: 615Á6; mean men: 62Á7 years, s.d. men: 610Á7) with recent-onset RA enrolled in a prospective observational cohort designated TIRA-1 (TIRA 5 a Swedish acronym for 'timely interventions in rheumatoid arthritis') [11] . Symptom duration was at least 6 weeks, but less than 12 months. At baseline (BL), all patients fulfilled the American College of Rheumatology (ACR) criteria for RA [27] . Five of 30 patients (17%) had radiographic changes at BL. The patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids, as considered appropriate by the physician [11] . A 28-joint disease activity score (DAS28) was calculated for all patients [28] and functional ability was assessed by the Health Assessment Questionnaire (HAQ) [29] . Serum samples were available from BL and from the 3-year follow-up (FU). Serum samples from 30 age-matched healthy blood donors (15 women, 15 men, mean age all 5 53Á0 years, s.d. all 5 8Á4, P 5 0Á16 compared to patients) from the same geographic area served as controls. Oral and written informed consent was obtained from all subjects, and the study protocol was approved by the local ethics committee in Link€ oping, Sweden.
Serological analyses
Rheumatoid factors of IgM and IgA class were analysed by enzyme immunoassay (EIA) (Autozyme RF IgM and IgA, respectively; Cambridge Life Sciences, Cambridge, UK). Anti-CCP of IgG and IgA class were analysed as described previously [11, 30] .
Analysis of IgG complexes
We employed an IgG capture enzyme-linked immunosorbent assay (ELISA) and detected the non-IgG proteins IgA, IgM, C3c, C1q and C-reactive protein (CRP) in IgG complexes. F(ab') 2 -fragment of goat anti-human IgG (Jackson Laboratories Immunoresearch, West Grove, PA, USA) was diluted in coating buffer (0Á1 M Na 2 CO 3 ,/NaHCO 3 , pH 9Á6) to 2 mg/ml and applied onto 96-well MaxiSorp TM microtitre plates (Nunc, Roskilde, Denmark; F96) at 48C overnight. After each incubation, three washing steps with phosphate-buffered saline (PBS) containing 0Á05% Tween-20 (Roth, Bonn, Germany; PBS-Tween) followed. We used 3% bovine serum albumin (BSA; Sigma-Aldrich, St Louis, MO, USA) in PBSTween at 378C for 2 h as blocking step. Subsequently, the plates were incubated with sera from patients with RA or from normal healthy donors (NHD) (1 : 1000 in PBS-Tween) at 378C for 2 h. Saturating binding of IgG complexes to the plates was achieved (Supporting information, Fig. S2 ). For the detection of IgG and non-IgG components of IgG complexes we employed horseradish peroxidase (HRP)-labelled antibodies against human IgG (Southern Biotech), human IgA (Southern Biotech), human IgM (Southern Biotech, Birmingham, AL, USA), human C1q (Abcam, Cambridge, MA, USA), human C3c (Abcam) or human C-reactive protein (CRP) (Abcam). The detection antibodies were diluted in PBS-Tween with final concentrations as recommended by the manufacturer and incubated at 378C for 1 h. The colour reaction was started by the addition of substrate solution (0Á1 M Na 2 HPO 4 , 0Á05 M citrate acid monohydrate, 0.02% H 2 O 2 and 100 mg/ml tetra-methyl benzidine, pH 5 5; Merck, Kenilworth, NJ, USA). After 10 min the reaction was stopped with 25% sulphuric acid (Merck). Optical density values were measured by a plate reader (Tecan infinite F200 Pro) at 450 nm with 620 nm reference wavelength. Samples were measured in triplicates on three different plates and the values were normalized by a mean plate absorbance factor. 
Detection of lectin binding sites on IgG complexes
To detect specific glycan structures exposed on IgG complexes we conducted IgG capture lectin ELISA immobilizing IgG complexes and detecting glycan accessibility using the lectins AAL pecific for fucosyl residues, fucosylated trimannose N-glycan cores, and sialic acid, respectively [31] [32] [33] . By using a N-acetylgalactosamine-lectin (GalNAc-L) we detected O-glycosidically linked (b1-3) galactose and N-acetylgalactosamine [34] . The coating of the plates with anti-human IgG F(ab') 2 -fragment was performed as described above. For blocking, a special blocking buffer (3% deglycosylated gelatin, 0Á1% CaCl 2 , 0Á1% MgCl 2 , 0.05% Tween-20) was applied onto the plates at 378C for 2 h, as described previously. Briefly, deglycosylation of gelatin was achieved by treatment with 1% periodic acid (Merck) for 24 h and subsequent dialysis against Tris-buffered saline containing 0Á1% CaCl 2 and 0Á1% MgCl 2 (TBS-Ca-Mg) [23] . After each incubation step, plates were washed three times with TBS-Ca-Mg and 0.05% Tween-20. Sera from patients with RA or NHD were diluted 1 : 1000 in TBS-Ca-MgTween and incubated at 378C for 2 h. Saturated binding of IgG complexes to the microtitre plates was confirmed by detection of human IgG (Supporting information, Fig. S2 ). To characterize the glycan exposure of captured IgG complexes we used biotin-labelled lectins AAL (100 ng/ml), LCA (100 ng/ml), galactose/N-acetylgalactosamine (GalNac-L) (1Á1 ng/ml) and SNA (100 ng/ml), respectively. Plates were incubated at room temperature for 1 h and then washed three times. In order to detect lectin binding, HRPconjugated streptavidin (Jackson Laboratories Immunoresearch) was employed, according to the manufacturer's instructions. After incubation for 1 h at room temperature, colorimetric analysis was performed as described above. The procedure of lectin-based ELISA has been described previously in detail [23] . Samples were measured in triplicate on three different plates and the values were normalized by a mean plate absorbance factor. The coefficients of variation for each lectin-ELISA are shown in Supporting information, Fig. S3 . All assays were performed under native conditions in order to obtain relevant information about the in-vivo accessibility of ligand binding sites exposed under non-denaturing conditions.
Statistical analysis
A two-sample t-test assuming unequal variance was used for the analysis of variations in IgG complex reactivity with detection antibodies and lectins. SPSS statistical software was used for statistical analysis of dependency of treatment and sex and for correlation analyses. Correlation between reactivity with detection antibodies or lectins and clinical and laboratory data were tested using Spearman's rank correlation test. Multiple sample correction by Bonferroni was applied to t-tests and Spearman's test. The fourfold table analysis of SNA/GalNac-L reactivity ratio was performed with the v 2 test and Yates' correction. Differences among treatment subgroups were evaluated with the KruskallWallis test with multiple sample correction by Dunn.
Results
Serum IgG derived from patients with RA was complexed with IgM-RF, CRP and the complement proteins C1q and C3c
First, we performed sandwich ELISA catching human IgG and detected IgG-associated proteins and glycans in the serum of 30 patients with recent-onset RA at baseline (BL) and after 36 months (follow-up, FU). Saturating binding of IgG complexes to the plates was achieved (Supporting information, Fig. S2 ). The reactivity of IgG complexes with LCA, SNA, GalNAc-L, C3c, C1q and CRP showed no dependency on sex and age (data for age not shown) of the patients with RA, as shown in Table 1 . During the 3-year FU, IgG complex reactivity with SNA and GalNAc-L were increased significantly (male: P 5 0Á008; female: P 5 0Á003) and decreased (male: P 5 0Á004; female: P 5 0Á014), respectively. These differences were independent of gender at each time-point. Interestingly, only male patients presented a significant increase of reactivity with AAL at FU (P 5 0Á03). Expectedly, when detecting IgG-associated IgM (equal to RF), we found significantly higher levels of IgM bound to IgG in patients compared to NHD (BL: P 5 0Á0007; FU: P 5 0Á0004; combined: P < 0Á0001) (Fig. 1a) . Unsurprisingly, a strong and significant correlation of IgG-bound IgM with clinically assessed IgM-RF analysis was found (BL: P 5 0Á002; FU: P < 0Á0002). Similarly, we observed a correlation of IgG-bound IgM and anti-CCP IgG autoantibody titres (BL: P 5 0Á049; FU: P < 0Á04) ( Table 2 ). IgM was not the only protein bound to IgG in patients with RA. Patients also had increased reactivity for CRP complexed with IgG (baseline: P < 0Á0001; FU: P < 0Á0001; combined: P < 0Á0001) compared to NHD. Furthermore, analysis of complement factor components revealed that C1q is bound to IgG from patients to a significantly higher extent when compared with NHD (baseline: P 5 0Á03; FU: P 5 0Á03; combined: P 5 0Á002) (Fig. 1b) . Binding of the complement factor component C3c to IgG was also increased in RA patients (BL: P 5 0Á04; FU: P > 0Á05; combined: P 5 0Á02).
Fucosyl residues and fucosylated tri-mannose N-glycan core sites on IgG complexes were increased in patients with RA
Lectin binding of fucosyl residues by AAL and of fucosylated tri-mannose N-glycan by LCA was higher in IgG derived from RA patients than from NHD (AAL: BL: P 5 0Á02; FU: P 5 0Á01; combined: P 5 0Á002; LCA: BL: P 5 0Á03; FU: P 5 0Á01; combined: P 5 0.001) (Fig. 2) .
Fucose accessibility, assessed by AAL binding, was altered significantly between male and female patients at follow-up (P 5 0Á03). When correlating AAL and LCA signals to other clinical and laboratory parameters, we found a strong correlation between LCA and anti-CCP IgG (P 5 0Á001) or anti-CCP IgA antibodies (P 5 0Á012) as well as IgM-RF (P 5 0Á043) or IgA-RF (P 5 0Á002) at baseline ( Table 2) . AAL correlated significantly with anti-CCP IgG levels (P 5 0Á003) ( Table 2 ). Similar correlations for LCA were observed at follow-up (Table 2 ). These results suggest that anti-CCP antibodies and RF are responsible for the higher exposure of fucosylated tri-mannose N-glycan core sites on IgG complexes in patients with RA.
The SNA/GalNAc-L ratio changed during antirheumatic treatment Next, we analysed binding of SNA and GalNAc-L to IgG complexes, thereby identifying sialic acid and galactose residues, respectively. As depicted in Fig. 3 , patients with RA showed a significantly higher exposure of sialic acid (BL: P < 0Á0001; FU: P < 0Á0001; combined: P < 0Á0001) and GalNAc-L binding sites (BL: P < 0Á0001; FU: P < 0Á0001; combined: P < 0Á0001) on IgG complexes at baseline and follow-up compared to NHD. Interestingly, reactivity with the SNA lectin increased significantly during treatment of RA in both genders (BL versus FU: P 5 0Á001). Conversely, the reactivity to GalNAc-L decreased significantly during therapy (BL versus FU: P 5 0Á0003) in males and females.
To demonstrate more clearly the changes in the exposure of sialic acid and O-glycosidically linked (b1-3) galactose 
Upper value 5 Spearman's correlation coefficient; lower value 5 P-value; IgA-cyclic citrullinated peptides (CCP) 5 IgA-antibodies to CCP; IgG-CCP 5 IgG-antibodies to CCP, RF 5 rheumatoid factor; ESR 5 erythrocyte sedimentation rate; CRP 5 serum C-reactive protein; DAS 28 5 disease activity score 28 for rheumatoid arthritis; HAQ 5 health assessment questionnaire; AAL 5 Aleuria aurantia lectin; LCA 5 Lens culinaris agglutinin; SNA 5 Sambucus nigra agglutinin; GalNAc-L 5 d-galactose, N-acetyl galactosamine. P-values shown after Bonferroni correction (*17).
and N-acetylgalactosamine on IgG complexes over time, we calculated the SNA/GalNAc-L ratio (Fig. 4a,b) . This ratio distinguished patients clearly before and after treatment (BL versus FU: P < 0Á0001). The SNA/GalNAc-L ratio remained either constant or increased in 26 patients with RA during therapy, whereas only four patients showed a slight decrease (BL versus FU: P < 0Á0001) (Fig. 4b) . Analysing associations between specific anti-rheumatic treatment and the SNA/GalNAc-L ratio, we found a significant increase of the SNA/GalNAc-L ratio in patients receiving treatment with glucocorticoids ( Fig. 5; P < 0Á001) .
For control purposes we tested whether GalNAc-L binding is related to IgG-IgA complexes [35] . We neither observed a correlation between IgG-bound IgA molecules and the reactivity with GalNAc-L nor significant differences in the amount of IgA molecules present in IgG complexes (Table 1, Supporting information, Fig. S4 ). Rather, therefore, the reactivity of IgG complexes with GalNAc-L can be explained by the changes of O-glycosidically linked (b1-3) galactose and N-acetylgalactosamine exposure on IgG complex constituents other than IgA.
Discussion
Herein, we characterized native IgG complexes from RA patients and determined whether they are associated with other immunoglobulins such IgM or other proteins such as complement factor components C1q and C3c and the pentraxin CRP. Furthermore, we characterized the binding of lectins to native complexed IgG to test for accessible fucosyl, galactosyl and sialic acid residues. We analysed these structural features of native IgG complexes in RA patients at the start of their disease and after 3 years of treatment. Recently, we showed that patients with SLE exhibit IgG complexes with increased AAL and LCA reactivity and that AAL accessibility is associated with disease activity [23] .
A complex formation of native IgG with IgM was expected to be found in RA patients representing IgM-RF. Indeed, results on IgM complexed with IgG reflected the data obtained by standard IgM-RF testing and also The studied cohort was divided into four groups according to the period of time receiving glucocorticoid therapy. The first group did not receive glucocorticoids during the whole observation period (steroid 0/0), patients starting glucocorticoid therapy after enrolment (steroid 0/1), patients who were treated with glucocorticoids at the time of inclusion but were withdrawn later (steroid 1/0) and patients receiving glucocorticoids during the whole study period (steroid 1/1). A significant increase of the SNA/ GalNAc-L binding ratio was observed only for the patients who were treated with glucocorticoids over the entire period.
correlated with anti-CCP IgG levels, which together with RF are associated strongly with a severe disease course in RA [36] . In addition, we found complexes of IgG with C1q and C3c. This observation may reflect the constant activation of the complement system in patients with RA. Clearance of immune complexes is mediated via C3 fragments and their binding to the erythrocyte-borne C3b/C4b receptor CR1. The circulating erythrocyte-bound immune complexes are cleared subsequently in the liver or spleen, thus preventing immune complex deposition and tissue damage [37] . Therefore, in patients with RA, circulating IgG complexes might expose enough C3b for their efficient clearance from the bloodstream, which is not the case in patients with SLE [23] . Despite the role of classical complement activation in RA remaining unclear, the presence of complement cleavage products bound to circulating immune complexes suggests a certain level of complement activation in RA.
IgG also forms complexes with CRP in RA patients. Similarly, complexes consisting of antibodies against CRP have been described in lupus nephritis [38] . In contrast to SLE [23] , CRP itself appears to associate with IgG in RA. CRP is elevated chronically in RA and has shown to contribute to bone destruction [39] . Nielen et al. reported that patients with RA have higher levels of serum CRP during the 2 years before diagnosis and that patients carrying anti-CCP autoantibodies show slightly higher concentrations of serum CRP than patients lacking these autoantibodies [36] .
Glycosylation of IgG essentially impacts its function and pathogenicity [40] . Several studies demonstrated that variations in the galactosylation and sialylation status of IgG influence disease activity in RA [1] [2] [3] . However, most of these studies analysed the presence of glycans on denatured and proteolytically cleaved fragments of IgG. Additionally, in these studies IgG was purified and therefore not complexed to other serum proteins, thus not reflecting the invivo situation. In this study, we characterized the carbohydrate pattern of native IgG resembling the in-vivo accessibility of glycans on IgG molecules to effector cells. We showed recently that patients with SLE exhibit IgG complexes with increased AAL and LCA reactivity and that AAL accessibility is associated with disease activity [23] . Here, we show that patients with RA also exhibit stronger binding of AAL and LCA to IgG complexes than NHD. This observation suggests an increased exposure of fucosyl residues and the fucosylated tri-mannose N-glycan core on immune complexes in RA, which might be a result of the higher protein content of immune complexes in patients. It has been shown previously using denaturing methods that IgG heavy chains exhibit increased fucosylation [41] in RA and that fucose determines the binding to FcgRIIIA (CD16a), and hence antibody-dependent cellular cytotoxicity (ADCC) [42, 43] . As these findings were achieved using mass spectrometry or electrophoretic separation, they do not necessarily represent the in-vivo exposure of certain glycans by immune complexes [23] . Our results provide evidence that fucose is indeed exposed and may affect the interaction of immune complexes with effector cells.
We also detected a significant increase of AAL reactivity after 3 years FU between male versus female RA patients. This is particularly interesting in the light of previous findings that the FcgRIIIA-158VV genotype, which is associated with higher IgG immune complex binding affinity, is also associated with a more severe disease course in male, but not female, RA patients [44, 45] . FcgRIIIA, expressed on natural killer cells, monocytes, macrophages and neutrophils, is known to primarily bind IgG-containing immune complexes [46] . Furthermore, copy number variation (CNV) of FCGR3B, the gene encoding FcgRIIIB receptor, also expressed on neutrophils [47] , has been associated with glomerulonephritis in SLE [48] and with the development of systemic autoimmunity [49] . In this context, the increased accessibility of fucose residues may modify the activation modus of FcgRIIIA and FcgRIIIB receptors on effector cells such as neutrophils, monocytes and macrophages.
IgG complexes from patients with RA exhibited a significantly elevated exposure of both sialic acid (SNA) and GalNAc (GalNAc-L) residues compared to healthy individuals. Interestingly, the exposure of sialylated sites on IgG complexes increased significantly during follow-up. The association of increased SNA and GalNAc-L reactivity and a clinical amelioration of the disease during the study period support the protective and anti-inflammatory impact of immunoglobulin sialylation in autoimmunity and suggests a pathogenetic role of IgG O-glycosylation. A protective effect of increased sialylation of autoreactive and total IgG has been described in anti-phospholipid syndrome [16] and RA [2, 3] , respectively. A recent study revealed that sialic acid residues on IgG facilitate its binding to the Ctype lectin receptor SIGN-R1 on regulatory macrophages in a RA mouse model [50] . This resulted in an upregulation of the inhibitory FcgRIIB on effector macrophages, thus dampening the proinflammatory actions of IgG. Furthermore, it has been shown that the production of antigen-specific IgG rich in sialic acid is driven by the induction of tolerance to the specific antigen and that this sialylated IgG prevents proinflammatory T and B cell responses [51] . Erythrocyte-bound IgG complexes are not present in sera and therefore are not analysed in our study. Nevertheless, we suggest that an altered sialylation of IgG complexes may modify its interaction with macrophages, proinflammatory T and B cells and erythrocytes, and consequently alter the pathogenic impact of IgG immune complexes and erythrocyte clearance [52] .
We also observed a significant increase in the exposure of O-glycosidically linked (b1-3) galactose and Nacetylgalactosamine in the serum of patients with RA. The three major components of GalNAc-L-binding O-glycosidically linked oligosaccharides are N-acetylgalactosamine, Nacetylglucosamine and galactose. Agalactosylated IgG Nglycans are always associated with a lack of terminal sialic acids [13] . Whether this is cause or consequence of the ongoing inflammation in RA remains to be clarified. Similar information about O-glycan variations in RA and other autoimmune diseases is scarce. Wada et al. reported that not only N-glycans but also O-glycans on IgG display a significant reduction in their GalNAc content in RA patients [53] . Altered O-glycosylation of IgA molecules is suspected to be an antigen for endogenous IgG in IgA nephropathy leading to immune complex formation [35] . In contrast to our results, these data were generated applying denaturing conditions and, therefore, were not reflecting the in-vivo accessibility of glycans for surface lectins of effector cells. In our assays, the increased reactivity of IgG complexes with GalNAc-L and its decline during therapy represents the actual alterations of the exposure of GalNAc, GlcNAc and galactose on IgG O-glycans. It has also been demonstrated that Ig O-glycosylation protects the glycoprotein from proteolytic cleavage [54] . According to this, therapy of patients with RA might lead to a reduction of the accessibility of IgG O-glycans, making it less vulnerable to proteolytic cleavage.
We also discovered a significant increase of the SNA/GalNAc-L ratio for patients who received glucocorticoid therapy between inclusion and follow up (P < 0Á0001). Previous studies have also shown increased protein sialylation in patients treated with hydrocortisone [55] . We suggest that the alteration of the IgG complex glycan in patients with RA might be related to glucocorticoid therapy. Decline of the GalNAc-L reactivity by glucocorticoid therapy may increase the susceptibility of the IgG complex to be cleared and may therefore contribute to successful abrogation of inflammation in RA. Hence, some of the sustained anti-inflammatory properties of glucocorticoids may be due to glycan alterations, i.e. increase in IgG sialylation and decrease in GalNAc-L binding glycans.
In conclusion, we report that patients with RA exhibit a particular glycan composition of IgG complexes including associated non-IgG molecules. We found that the increased exposure of fucosylated tri-mannose N-glycan core sites in the IgG of RA patients is related to higher autoantibody titres. We also demonstrate that native complexed IgG of RA patients shows substantial changes in the exposure of sialic acid and O-linked galactosylic residues and that these changes fluctuate over time following pharmacotherapy. Specifically, the SNA/GalNAc-L ratio appears to be an indicator for the efficacy of glucocorticoid therapy. Taken together, our study provides important information about the composition and accessibility of specific carbohydrate residues on native IgG complexes showing that glycans can be recognized by soluble lectins in the circulation, thereby modulating the complement cascade and activation of myeloid effector cells.
This ex-vivo analysis of native IgG complexes complements the molecular deciphering of the glycosylation patterns of denatured IgG heavy chain fragments.
Supporting information
Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Fig. S1 . Composition of native immunoglobulin (Ig)G complexes and their putative glycosylation sites. This scheme shows (1) the canonical glycans attached to the IgG-CH2-domain, (2) the glycans attached to some VH and CH1 domains, (3) putative sites of hyperglycosylation, (4) increased accessibility for lectin binding of the canonical glycans attached to the CH2-domains 23 and (5) that glycans can also be exposed by IgGassociated molecules exemplified by IgA, IgM, C1q, C3d and C-reactive protein (CRP). 
